Structure-based drug design of pre-clinical candidate nanopiperine: a direct target for CYP1A1 protein to mitigate hyperglycaemia and associated microbes.

MLA

Dey, R., et al. “Structure-Based Drug Design of Pre-Clinical Candidate Nanopiperine: A Direct Target for CYP1A1 Protein to Mitigate Hyperglycaemia and Associated Microbes.” SAR & QSAR in Environmental Research, vol. 35, no. 11, Nov. 2024, pp. 1071–93. EBSCOhost, https://doi.org/10.1080/1062936X.2024.2434934.

APA

Dey, R., Saha, S., Molla, S. H., Nandi, S., & Samadder, A. (2024). Structure-based drug design of pre-clinical candidate nanopiperine: a direct target for CYP1A1 protein to mitigate hyperglycaemia and associated microbes. SAR & QSAR in Environmental Research, 35(11), 1071–1093. https://doi.org/10.1080/1062936X.2024.2434934

Chicago

Dey, R., S. Saha, S.H. Molla, S. Nandi, and A. Samadder. 2024. “Structure-Based Drug Design of Pre-Clinical Candidate Nanopiperine: A Direct Target for CYP1A1 Protein to Mitigate Hyperglycaemia and Associated Microbes.” SAR & QSAR in Environmental Research 35 (11): 1071–93. doi:10.1080/1062936X.2024.2434934.